Circulating exosomal long noncoding RNA PRINS-First findings in monoclonal gammopathies

Hematol Oncol. 2018 Dec;36(5):786-791. doi: 10.1002/hon.2554. Epub 2018 Sep 13.


Multiple myeloma is the second most common hematological malignancy characterized by focal lesions of malignant plasma cells in the bone marrow. These lesions contain subclones that directly influence survival of patients. Bone marrow biopsies are single-site biopsies and thus cannot contain all information about the tumor. In contrast, liquid biopsies analyze circulating cells and molecules that are secreted from all sites of the tumor. Long noncoding RNA molecules are one class of these molecules. We performed a two-phase biomarker study investigating lncRNA expression profiles in exosomes of peripheral blood serum of newly diagnosed multiple myeloma (MM) patients, monoclonal gammopathy of undetermined significance (MGUS) patients in comparison with healthy donors (HD). Surprisingly, this analysis revealed dysregulation of only one exosomal lncRNA PRINS in MM vs HD. Overall, MM and MGUS patients were distinguished from HD with sensitivity of 84.9% and specificity of 83.3%. Our study suggests a possible diagnostic role for exosomal lncRNA PRINS in monoclonal gammopathies patients.

Keywords: biomarker; long noncoding RNA; monoclonal gammopathy of undetermined significance; multiple myeloma; qPCR.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Disease-Free Survival
  • Exosomes / metabolism*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma* / blood
  • Multiple Myeloma* / diagnosis
  • Multiple Myeloma* / mortality
  • RNA, Long Noncoding / blood*
  • RNA, Neoplasm / blood*
  • Survival Rate


  • RNA, Long Noncoding
  • RNA, Neoplasm